Integrase Strand Transfer Inhibitors in HIV TherapyReport as inadecuate

Integrase Strand Transfer Inhibitors in HIV Therapy - Download this document for free, or read online. Document in PDF available to download.

Infectious Diseases and Therapy

, Volume 2, Issue 2, pp 83–93

First Online: 19 November 2013Received: 02 October 2013


HIV drug resistance has been one of the major obstacles to HIV eradication and has contributed to the need for the constant development of new antiretroviral drugs over the past 25 years. With the recent approval of dolutegravir for human therapy by the U.S. Food and Drug Administration, health practitioners may soon have access to three integrase strand transfer inhibitors to treat individuals living with HIV. Here, we review the use of raltegravir, elvitegravir, and dolutegravir for use in first- and second-line HIV treatment regimens and the issue of HIV resistance against integrase inhibitors.

KeywordsDolutegravir Elvitegravir HIV Infectious disease Integrase inhibitors Raltegravir Resistance Sequencing Electronic supplementary materialThe online version of this article doi:10.1007-s40121-013-0020-8 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Thibault Mesplède - Mark A. Wainberg


Related documents